Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type

Human Cell

Volumn 20, Issue 3, 2007, Pages 85-90

  Ninomiya, Kouzou ^a   Ohi, Satoshi ^a   Tabei, Isao ^a   Jin, Song ^a   Tachibana, Toshiaki ^a   Yamashita, Shigeo ^a   Yanaga, Katsuhiko ^a   Hashimoto, Hisashi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Cell line; Establishment; HER 2; Invasive ductal carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CASE REPORT; CELL GROWTH; CELL LINE; CHROMOSOME ANALYSIS; CYTOPLASM; DESMOSOME; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PHASE CONTRAST MICROSCOPY; PLEURA EFFUSION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENT CANCER; TUMOR CELL CULTURE; XENOTRANSPLANTATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MICE; MICE, NUDE; MICROSCOPY, ELECTRON; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PLEURAL EFFUSION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

MUS MUSCULUS;

EID: 34447524114     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1111/j.1749-0774.2007.00033.x     Document Type: Article

References (9)

1. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244: 707 12.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235: 177 82.
3. Vang R, Cooley LD, Harrison WR et al. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol 2000 113: 669 74.
4. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N et al. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Saudi Med J 2006 27: 1810 14.
5. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 369: 29 36.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 353: 1659 72.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 354: 809 20.
8. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006 1: 4 12.
9. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 23: 5305 13.